Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06875700 · ClinicalTrials.gov registry record
Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients
A clinical trial of Leiomyosarcoma, sponsored by University of Utah.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06875700: Recruiting study of Leiomyosarcoma, sponsored by University of Utah.
NCT06875700 is a study of Leiomyosarcoma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 300 participants, above the 103-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (191% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06875700, a study of Leiomyosarcoma, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients. This study is assessing the beliefs about the heritability of leiomyosarcoma and other cancer risks, and attitudes towards germline testing among leiomyosarcoma patients.
Primary Outcome
This outcome will report the count of participants who self-reported a strong belief in heritability. Participants who responded on a questionnaire that sarcoma is somewhat or highly heritable are considered to have a strong belief in heritability. This outcome measure will be assessed on Day 1 of the study.
Conditions Studied
Study Locations (1)
Utah
- Huntsman Cancer Institute at the University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2027-08 |
What NCT06875700 shows while recruiting
NCT06875700 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 103-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (191% higher).
The record links to 1 condition, with Leiomyosarcoma appearing as the primary indexed condition, and to 0 interventions.
NCT06875700 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06875700 about?
NCT06875700 is a clinical study titled "Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients". Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients. This study is assessing the beliefs about the heritability of leiomyosarco...
What is the current status of trial NCT06875700?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-07-09. Estimated completion is 2027-08.
What conditions does trial NCT06875700 study?
This clinical trial studies the following conditions: Leiomyosarcoma.
Who is sponsoring clinical trial NCT06875700?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06875700 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06875700's enrollment target sits among peer trials
300 3rd of 16 higher than 14 of 16 other Leiomyosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leiomyosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Localized Leiomyosarcoma Biomarker Protocol
RECRUITING
-
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
RECRUITING · Phase 3
-
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RECRUITING · Phase 3
-
Metastatic Leiomyosarcoma Biomarker Protocol
RECRUITING
-
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
RECRUITING · Phase 2
-
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI